MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Gossamer Bio Inc

Geschlossen

BrancheGesundheitswesen

1.24 0.81

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.19

Max

1.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.6M

-37M

Verkäufe

510K

9.9M

EPS

-0.16

Gewinnspanne

-370.492

Angestellte

144

EBITDA

-1.9M

-34M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+611.38% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

32M

282M

Vorheriger Eröffnungskurs

0.43

Vorheriger Schlusskurs

1.24

Nachrichtenstimmung

By Acuity

60%

40%

324 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Juli 2025, 23:09 UTC

Ergebnisse

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1. Juli 2025, 19:16 UTC

Akquisitionen, Fusionen, Übernahmen

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1. Juli 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1. Juli 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1. Juli 2025, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie: Deal Represents Implied Value of $8.4 Billion

1. Juli 2025, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1. Juli 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie Completes Acquisition of AZEK

1. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. Juli 2025, 20:24 UTC

Ergebnisse

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1. Juli 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1. Juli 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1. Juli 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1. Juli 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1. Juli 2025, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1. Juli 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1. Juli 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1. Juli 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1. Juli 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1. Juli 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1. Juli 2025, 17:01 UTC

Akquisitionen, Fusionen, Übernahmen

Danone Completed Acquisition of Majority Stake in Kate Farms

1. Juli 2025, 16:55 UTC

Ergebnisse

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1. Juli 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1. Juli 2025, 16:25 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juli 2025, 15:48 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1. Juli 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1. Juli 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1. Juli 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1. Juli 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

611.38% Vorteil

12-Monats-Prognose

Durchschnitt 8.75 USD  611.38%

Hoch 15 USD

Tief 4 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

324 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.